knowledge -WSS

knowledge

author：focus 2025-08-24 23:27:45 - browse：937

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Trial using CRISPR to edit HIV out of cells disappoints

entertainment

WSS

Oprah kicked off a national conversation on obesity. Let's have it

Covid silver lining: Unprecedented look at human immune system

Primary care physicians play key roles in Alzheimer's management

Four alarming medical procedures we’re glad history forgot

Scientists uncover potential path to treating deadly childhood tumor

Scientists boost immune system in aging mice by making it youthful

focus

knowledge

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Decaf coffee targeted by food safety group under obscure FDA rule

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Alkermes shareholders re

Young boy dies in trial for Pfizer Duchenne gene therapy

BioMarin wins approval for gene therapy to treat hemophilia A

Oprah kicked off a national conversation on obesity. Let's have it

Cancer drug shortages should be causing more outrage

Scientists uncover potential path to treating deadly childhood tumor

focus

Overprescribed: High cost isn't America's only drug problem

Alzheimer's risk factor APOE4 may be a distinct form of the disease

There's no autism epidemic. It's an autism diagnosis epidemic

Readout Newsletter: Merck, Vertex, and Viking updates

The Readout: Lenmeldy, GLP

Young boy dies in trial for Pfizer Duchenne gene therapy

entertainment

hotspot

entertainment

Wikipedia